127 related articles for article (PubMed ID: 22468921)
21. Alleviation of myelodysplastic syndrome-associated skin rush after treatment with decitabine.
Papaioannou M; Sapalidis K; Kotoula V
Eur J Haematol; 2008 Dec; 81(6):489-90. PubMed ID: 18691250
[No Abstract] [Full Text] [Related]
22. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
[TBL] [Abstract][Full Text] [Related]
23. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.
Szpurka H; Jankowska AM; Makishima H; Bodo J; Bejanyan N; Hsi ED; Sekeres MA; Maciejewski JP
Leuk Res; 2010 Aug; 34(8):969-73. PubMed ID: 20334914
[TBL] [Abstract][Full Text] [Related]
24. Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.
Salim O; Toptas T; Avsar E; Yucel OK; Ozturk E; Ferhanoglu B; Geduk A; Mehtap O; Tombak A; Tiftik EN; Deveci B; Kurtoglu E; Kara O; Atagunduz IK; Tuglular TF; Undar L
Leuk Res; 2016 Jun; 45():82-9. PubMed ID: 27107658
[TBL] [Abstract][Full Text] [Related]
25. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Long B; Shi H; Zhu C
Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
[No Abstract] [Full Text] [Related]
26. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
Jeromin S; Haferlach T; Weissmann S; Meggendorfer M; Eder C; Nadarajah N; Alpermann T; Kohlmann A; Kern W; Haferlach C; Schnittger S
Haematologica; 2015 Apr; 100(4):e125-7. PubMed ID: 25527566
[No Abstract] [Full Text] [Related]
27. Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts.
Baumann Kreuziger LM; Wolanskyj AP; Hanson CA; Steensma DP
Eur J Haematol; 2011 Jun; 86(6):512-6. PubMed ID: 21388451
[TBL] [Abstract][Full Text] [Related]
28. Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS).
Montalban-Bravo G; Kanagal-Shamanna R; Darbaniyan F; Siddiqui MT; Sasaki K; Wei Y; Yang H; Chien KS; Naqvi K; Jabbour E; Kadia TM; Daver N; DiNardo C; Ravandi F; Pemmaraju N; Bose P; Verstovsek S; Pierce S; Bueso-Ramos C; Patel K; Do KA; Kantarjian H; Garcia-Manero G
Am J Hematol; 2021 Jul; 96(7):E246-E249. PubMed ID: 33811786
[No Abstract] [Full Text] [Related]
29. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
[No Abstract] [Full Text] [Related]
30. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts.
Visconte V; Makishima H; Jankowska A; Szpurka H; Traina F; Jerez A; O'Keefe C; Rogers HJ; Sekeres MA; Maciejewski JP; Tiu RV
Leukemia; 2012 Mar; 26(3):542-5. PubMed ID: 21886174
[No Abstract] [Full Text] [Related]
31. CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts.
Patnaik MM; Belachew A; Finke C; Lasho TL; Hanson CA; Tefferi A
Leukemia; 2014 Jun; 28(6):1370-1. PubMed ID: 24476767
[No Abstract] [Full Text] [Related]
32. Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis.
Caocci G; La Nasa G; Bain BJ
Am J Hematol; 2016 Oct; 91(10):1056. PubMed ID: 27301073
[No Abstract] [Full Text] [Related]
33. High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.
Jeromin S; Haferlach T; Grossmann V; Alpermann T; Kowarsch A; Haferlach C; Kern W; Schnittger S
Haematologica; 2013 Feb; 98(2):e15-7. PubMed ID: 22929973
[No Abstract] [Full Text] [Related]
34. Primary acquired sideroblastic anemia, thrombocytosis, and trisomy 8.
Patel K; Kelsey P
Ann Hematol; 1997 Apr; 74(4):199-201. PubMed ID: 9174550
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation.
Nichele I; Ruggeri M; Rodeghiero F
Am J Hematol; 2015 Aug; 90(8):E148-9. PubMed ID: 25963624
[No Abstract] [Full Text] [Related]
36. [Refractory anemia, thrombocytosis and deletion of the long arm of chromosome 5].
Fernández Martín J; Barbado FJ; Díaz Pérez MA; Vázquez Rodríguez JJ
Med Clin (Barc); 1985 Sep; 85(8):345. PubMed ID: 4068829
[No Abstract] [Full Text] [Related]
37. Refractory anemia with ringed sideroblasts associated with thrombocytosis: comparative analysis of marked with non-marked thrombocytosis, and relationship with JAK2 V617F mutational status.
Raya JM; Arenillas L; Domingo A; Bellosillo B; Gutiérrez G; Luño E; Piñán MA; Barbón M; Pérez-Sirvent ML; Muruzábal MJ; Yánez L; García L; Lemes A; Navarro JT; Elosegi A; Cortés MA; Villegas A; Durán MA; Ardanaz M; Florensa L;
Int J Hematol; 2008 Nov; 88(4):387-395. PubMed ID: 18820995
[TBL] [Abstract][Full Text] [Related]
38. Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis.
Patnaik MM; Lasho TL; Finke CM; Hanson CA; King RL; Ketterling RP; Gangat N; Tefferi A
Leukemia; 2016 Nov; 30(11):2273-2275. PubMed ID: 27479179
[No Abstract] [Full Text] [Related]
39. A case of refractory anemia with ring sideroblasts and associated thrombocytosis.
Issa S; Ingley K
Blood; 2013 May; 121(21):4256. PubMed ID: 23844433
[No Abstract] [Full Text] [Related]
40. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts.
Cotter PD; May A; Fitzsimons EJ; Houston T; Woodcock BE; al-Sabah AI; Wong L; Bishop DF
J Clin Invest; 1995 Oct; 96(4):2090-6. PubMed ID: 7560104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
